1/12
07:00 am
agio
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
Low
Report
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
1/8
08:27 am
agio
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? [Yahoo! Finance]
Low
Report
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? [Yahoo! Finance]
1/6
01:30 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at JPMorgan Chase & Co. from $20.00 to $25.00. They now have a "neutral" rating on the stock.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at JPMorgan Chase & Co. from $20.00 to $25.00. They now have a "neutral" rating on the stock.
1/5
08:40 am
agio
Compass Therapeutics Announces Key Leadership Appointments [Yahoo! Finance]
Low
Report
Compass Therapeutics Announces Key Leadership Appointments [Yahoo! Finance]
1/5
07:00 am
agio
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Low
Report
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
12/30
04:09 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/26
03:57 pm
agio
Agios Pharmaceuticals price target raised to $34 from $32 at BofA [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals price target raised to $34 from $32 at BofA [Yahoo! Finance]
12/26
09:02 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/26
08:04 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $40.00 price target on by analysts at Leerink Partners.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $40.00 price target on by analysts at Leerink Partners.
12/25
10:47 am
agio
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK [Yahoo! Finance]
Low
Report
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK [Yahoo! Finance]
12/24
05:02 pm
agio
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript [Seeking Alpha]
Low
Report
Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript [Seeking Alpha]
12/24
02:01 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Neutral
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/24
01:14 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at Truist Financial Corporation from $32.00 to $38.00. They now have a "buy" rating on the stock.
Neutral
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at Truist Financial Corporation from $32.00 to $38.00. They now have a "buy" rating on the stock.
12/24
12:33 pm
agio
Here's Why Shares in Agios Pharmaceuticals Popped Today [Yahoo! Finance]
Low
Report
Here's Why Shares in Agios Pharmaceuticals Popped Today [Yahoo! Finance]
12/24
08:43 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at Bank of America Corporation from $32.00 to $34.00. They now have a "buy" rating on the stock.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at Bank of America Corporation from $32.00 to $34.00. They now have a "buy" rating on the stock.
12/23
07:45 pm
agio
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
High
Report
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
12/8
07:00 am
agio
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
Low
Report
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
12/5
10:29 pm
agio
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals [Yahoo! Finance]
Low
Report
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals [Yahoo! Finance]
11/29
07:16 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
11/26
02:01 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
06:04 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
11/25
08:53 am
agio
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst [Yahoo! Finance]
Low
Report
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst [Yahoo! Finance]
11/24
09:04 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $32.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) was given a new $32.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
agio
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/21
02:55 pm
agio
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at JPMorgan Chase & Co. from $37.00 to $20.00. They now have a "neutral" rating on the stock.
Low
Report
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at JPMorgan Chase & Co. from $37.00 to $20.00. They now have a "neutral" rating on the stock.